<DOC>
	<DOC>NCT02022683</DOC>
	<brief_summary>To compare the clinical outcomes of Endoscopic Lung Volume Reduction using Pulmonx Zephyr Endobronchial Valve (EBV) vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema patients in a controlled trial design setting.</brief_summary>
	<brief_title>To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Heterogeneous emphysema 15% pred &lt; or = FEV1 &lt; or = 45% pred TLC &gt; 100% and RV &gt; or = 180% 150 m &lt; or = 6MWT &lt; or = 450 m No collateral ventilation Contraindication to bronchoscopy Active pulmonary infection History of 2 or more exacerbations with hospitalization over the past 12 months Known pulmonary hypertension Prior LVR or LVRS procedure Pregnant or lactating woman Hypercapnia Current diagnosis of asthma &gt; 25 mg Prednisolon / day CV in the target lobe or inconclusive Chartis assessment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Endoscopic lung volume reduction</keyword>
	<keyword>Endobronchial valves</keyword>
</DOC>